Novartis

1 stories · following the connections

Business

Rhizen Pharmaceuticals Announces Exclusive Worldwide License Agreement for the Development and Commercialization of a Dual PI3K-delta gamma Inhibitor

By Nasdaq OMXDec 9, 2015, 12:00 PM UTC